Cardiovascular and Renal Outcomes of Integrated Management of Blood Pressure and Other Cardiometabolic Risks in Hypertensives：a Multicenter Prospective Cohort Study （UPDATE-cohort）
Trial Snapshot
- Phase
- Not Applicable
- Status
- Not yet recruiting
- Sponsor
- Huashan Hospital
- Enrollment
- 30,000
- Locations
- 1
- Primary Endpoint
- complex outcome
Study Overview
Brief Summary
this clinical trial is designed to study the cardiovascular and renal outcomes of hypertensives after an integrated management of blood pressure and other cardiometabolic risks. it is a multicenter prospective cohort study.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 18 Years to 80 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Outpatients from departments of Cardiology, Endocrinology, Nephrology, Neurology, Geriatrics or General Internal Medicine.
- •Diagnosed as hypertension. Diagnostic criteria: 1)The office BP measured at the day of visit and at least one time before that day were above the cut-off values ( ≥140 mmHg SBP and/or ≥90 mmHg DBP); 2)for patients with normal BP at the day of visit, they should have already been given pre-treatment with antihypertensive drugs ≥ 2 weeks.
- •Voluntary participation.
Exclusion Criteria
- •Patients aged< 18 years old.
- •Patients without a definite diagnosis of hypertension(for instance, if the patient has been taking antihypertensive drugs irregularly, it is difficult to confirm the diagnosis of hypertension).
- •Patients with a definite diagnosis of secondary hypertension.
- •Patients are diagnosed dyslipidemia with clear cause, such as nephrotic syndrome, severe hypothyroidism, terminal stage of malignancy, etc.
- •Patients are diagnosed end-stage renal disease, hemodialysis, and peritoneal dialysis patients.
- •Patients diagnosed with mental abnormalities who are unable to complete the questionnaire.
- •Patients have once participated in this research during this study cycle(to avoid repeated participation).
Outcomes
Primary Outcomes
complex outcome
Time Frame: follow-up 1 year
number of participants with 3P-MACE events(cardiovascular deaths, non-fatal myocardial infarction, non-fatal stroke)
coronary angioplasty
Time Frame: follow-up 1 year
number of participants with coronary angioplasty
acute renal failure
Time Frame: follow-up 1 year
number of participants with acute renal failure(eGFR decreases by 50% or \<15ml/min/1.73m2, dialysis or renal death)
acute heart failure
Time Frame: follow-up 1 year
number of participants with acute heart failure(non-scheduled hospitalizations due to heart failure or required intravenous medication)
Secondary Outcomes
No secondary outcomes reported
Investigators
Yong Li
Professor, MD, PhD
Huashan Hospital